Skip to content
Open Data Finder

Search results for sgl

FiltersOpen Government Canada
  1. Open Government Canada

    Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury

    Health Canada | Santé CanadaUpdated 10 May 2024

    … acute kidney injury and the use of two SGLT2 inhibitors, Invokana (canagliflozin) or Forxiga (dapagliflozin). This issue was …

    • HTML
  2. Open Government Canada

    Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects

    Health Canada | Santé CanadaUpdated 10 May 2024

    … risk of bone-related side effects of using SGLT2 inhibitors. The review was triggered by a notice about …

    • HTML
  3. Open Government Canada

    Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)

    Health Canada | Santé CanadaUpdated 10 May 2024

    Ketones are a type of waste product that the body creates when it breaks down fat to use …

    • HTML
  4. Open Government Canada

    Summary Safety Review - SGLT2 inhibitors - Assessing the potential risk of a rare brain condition (posterior reversible encephalopathy syndrome) in patients who have developed high levels of acids in the blood (diabetic ketoacidosis)

    Health Canada | Santé CanadaUpdated 10 May 2024

    … PRES in patients treated with SGLT2 inhibitors who have developed DKA. SGLT2 inhibitors have been linked to an …

    • HTML
“sgl” datasets · Open Data Finder